Aktis Oncology (NASDAQ:AKTS) Stock Has Average Price Target of $35.62

Aktis Oncology (NASDAQ:AKTS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $35.62.

A number of brokerages recently issued reports on AKTS. Raymond James Financial reissued a “strong-buy” rating on shares of Aktis Oncology in a report on Tuesday. Wall Street Zen downgraded shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. BMO Capital Markets began coverage on shares of Aktis Oncology in a report on Tuesday, August 18th. They issued an “outperform” rating and a $37.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $35.00 target price on shares of Aktis Oncology in a report on Friday, October 2nd. Finally, Oppenheimer began coverage on shares of Aktis Oncology in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $40.00 price target for the company.

Read Our Latest Research Report on AKTS

Institutional Trading of Aktis Oncology

Several institutional investors have recently made changes to their positions in AKTS. BlackRock Inc. grew its position in Aktis Oncology by 7.9% in the second quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock worth $73,431,000 after acquiring an additional 166,231 shares during the period. Blue Owl Capital Holdings LP increased its stake in Aktis Oncology by 8.9% during the third quarter. Blue Owl Capital Holdings LP now owns 3,343,827 shares of the technology company’s stock worth $65,104,000 after acquiring an additional 273,608 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Aktis Oncology during the second quarter worth $63,372,000. Jupiter Topco LLC purchased a new stake in Aktis Oncology in the second quarter valued at $42,359,000. Finally, State Street Corp raised its position in Aktis Oncology by 8.5% in the third quarter. State Street Corp now owns 1,050,480 shares of the technology company’s stock valued at $20,453,000 after purchasing an additional 82,460 shares during the period. Hedge funds and other institutional investors own 28.84% of the company’s stock.

Aktis Oncology Stock Down 1.5%

Shares of NASDAQ:AKTS opened at $16.15 on Friday. The business has a fifty day moving average of $17.70 and a two-hundred day moving average of $20.68. The stock has a market cap of $870.89 million and a P/E ratio of -11.87. Aktis Oncology has a 52-week low of $13.96 and a 52-week high of $34.19.

Aktis Oncology (NASDAQ:AKTS – Get Free Report) last issued its earnings results on Thursday, November 12th. The technology company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.07). Aktis Oncology had a negative return on equity of 26.86% and a negative net margin of 706.81%. The company had revenue of $3.91 million during the quarter, compared to analyst estimates of $4.87 million. On average, equities analysts anticipate that Aktis Oncology will post -1.97 earnings per share for the current year.

Aktis Oncology Company Profile

(Get Free Report)

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.

Featured Stories

Analyst Recommendations for Aktis Oncology (NASDAQ:AKTS)

Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.